About this Journal Submit a Manuscript Table of Contents
Journal of Oncology
Volume 2009 (2009), Article ID 349205, 10 pages
http://dx.doi.org/10.1155/2009/349205
Review Article

Prognostic and Therapeutic Potential of Nuclear Receptors in Head and Neck Squamous Cell Carcinomas

Department of Otorhinolaryngology, University of Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany

Received 12 March 2009; Accepted 13 July 2009

Academic Editor: Amanda Psyrri

Copyright © 2009 Shirley K. Knauer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Forastiere, R. Weber, and K. Ang, “Treatment of head and neck cancer,” The New England Journal of Medicine, vol. 358, no. 10, pp. 1077–1078, 2008.
  2. A. A. Forastiere, “Chemotherapy in the treatment of locally advanced head and neck cancer,” Journal of Surgical Oncology, vol. 97, no. 8, pp. 701–707, 2008. View at Publisher · View at Google Scholar · View at PubMed
  3. J. Bernier, “A multidisciplinary approach to squamous cell carcinomas of the head and neck: an update,” Current Opinion in Oncology, vol. 20, no. 3, pp. 249–255, 2008. View at Publisher · View at Google Scholar · View at PubMed
  4. B. M. Lippert, S. K. Knauer, V. Fetz, W. Mann, and R. H. Stauber, “Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential,” International Journal of Cancer, vol. 121, no. 6, pp. 1169–1174, 2007. View at Publisher · View at Google Scholar · View at PubMed
  5. A. A. Forastiere, A. Trotti, D. G. Pfister, and J. R. Grandis, “Head and neck cancer: recent advances and new standards of care,” Journal of Clinical Oncology, vol. 24, no. 17, pp. 2603–2605, 2006. View at Publisher · View at Google Scholar · View at PubMed
  6. A. A. Forastiere, K. K. Ang, D. Brizel, et al., “Head and neck cancers,” Journal of the National Comprehensive Cancer Network, vol. 6, no. 7, pp. 646–695, 2008.
  7. H. Gronemeyer, J.-Å. Gustafsson, and V. Laudet, “Principles for modulation of the nuclear receptor superfamily,” Nature Reviews Drug Discovery, vol. 3, no. 11, pp. 950–964, 2004. View at Publisher · View at Google Scholar · View at PubMed
  8. A. Schweitzer, S. K. Knauer, and R. H. Staubert, “Therapeutic potential of nuclear receptors,” Expert Opinion on Therapeutic Patents, vol. 18, no. 8, pp. 861–888, 2008. View at Publisher · View at Google Scholar
  9. B. Vogelstein and K. W. Kinzler, “Cancer genes and the pathways they control,” Nature Medicine, vol. 10, no. 8, pp. 789–799, 2004. View at Publisher · View at Google Scholar · View at PubMed
  10. K. Dahlman-Wright, V. Cavailles, S. A. Fuqua, et al., “International union of pharmacology. LXIV. Estrogen receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 773–781, 2006. View at Publisher · View at Google Scholar · View at PubMed
  11. C. K. Osborne and R. Schiff, “Estrogen-receptor biology: continuing progress and therapeutic implications,” Journal of Clinical Oncology, vol. 23, no. 8, pp. 1616–1622, 2005. View at Publisher · View at Google Scholar · View at PubMed
  12. H. Hamakawa, K.-I. Nakashiro, T. Sumida, et al., “Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer,” Head and Neck, vol. 30, no. 6, pp. 800–809, 2008. View at Publisher · View at Google Scholar · View at PubMed
  13. J. Lukits, É. Remenár, E. Rásó, A. Ladányi, M. Kásler, and J. Tímár, “Molecular identification, expression and prognostic role of estrogen- and progesterone receptors in head and neck cancer,” International Journal of Oncology, vol. 30, no. 1, pp. 155–160, 2007.
  14. P. Germain, B. Staels, C. Dacquet, M. Spedding, and V. Laudet, “Overview of nomenclature of nuclear receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 685–704, 2006. View at Publisher · View at Google Scholar · View at PubMed
  15. K. W. Trotter and T. K. Archer, “Nuclear receptors and chromatin remodeling machinery,” Molecular and Cellular Endocrinology, vol. 265-266, pp. 162–167, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. V. Perissi and M. G. Rosenfeld, “Controlling nuclear receptors: the circular logic of cofactor cycles,” Nature Reviews Molecular Cell Biology, vol. 6, no. 7, pp. 542–554, 2005. View at Publisher · View at Google Scholar
  17. G. Benoit, M. Malewicz, and T. Perlmann, “Digging deep into the pockets of orphan nuclear receptors: insights from structural studies,” Trends in Cell Biology, vol. 14, no. 7, pp. 369–376, 2004. View at Publisher · View at Google Scholar · View at PubMed
  18. L. Michalik and W. Wahli, “Guiding ligands to nuclear receptors,” Cell, vol. 129, no. 4, pp. 649–651, 2007. View at Publisher · View at Google Scholar · View at PubMed
  19. K. W. Nettles and G. L. Greene, “Ligand control of coregulator recruitment to nuclear receptors,” Annual Review of Physiology, vol. 67, pp. 309–333, 2005. View at Publisher · View at Google Scholar · View at PubMed
  20. K. Kourelis, G. Sotiropoulou-Bonikou, G. Vandoros, and I. Varakis, “Peroxisome proliferator-activated receptor γ expression correlates with the differentiation level of normal, premalignant, and malignant laryngeal squamous cells,” Journal of Otolaryngology, vol. 36, no. 5, pp. 283–290, 2007. View at Publisher · View at Google Scholar
  21. B. J. Deroo and K. S. Korach, “Estrogen receptors and human disease,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 561–570, 2006. View at Publisher · View at Google Scholar · View at PubMed
  22. A. Krishnan, S. A. Nair, and M. R. Pillai, “Biology of PPAR gamma in cancer: acritical review on existing lacunae,” Current Molecular Medicine, vol. 7, no. 6, pp. 532–540, 2007.
  23. Y. Yasui, M. Kim, and T. Tanaka, “PPAR ligands for cancer chemoprevention,” PPAR Research, vol. 2008, Article ID 548919, 10 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
  24. M. Lehrke and M. A. Lazar, “The many faces of PPARγ,” Cell, vol. 123, no. 6, pp. 993–999, 2005. View at Publisher · View at Google Scholar · View at PubMed
  25. W. A. Hsueh and D. Bruemmer, “Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease,” Hypertension, vol. 43, no. 2, pp. 297–305, 2004.
  26. L. Altucci, M. D. Leibowitz, K. M. Ogilvie, A. R. de Lera, and H. Gronemeyer, “RAR and RXR modulation in cancer and metabolic disease,” Nature Reviews Drug Discovery, vol. 6, no. 10, pp. 793–810, 2007. View at Publisher · View at Google Scholar · View at PubMed
  27. G. Kroemer and J. Pouyssegur, “Tumor cell metabolismml: cancer's Achilles' heel,” Cancer Cell, vol. 13, no. 6, pp. 472–482, 2008. View at Publisher · View at Google Scholar · View at PubMed
  28. T. Wang, J. Xu, X. Yu, R. Yang, and Z. C. Han, “Peroxisome proliferator-activated receptor gamma in malignant diseases,” Critical Reviews in Oncology/Hematology, vol. 58, no. 1, pp. 1–14, 2006.
  29. L. Fajas, M. B. Debril, and J. Auwerx, “Peroxisome proliferator-activated receptorgamma: from adipogenesis to carcinogenesis,” Journal of Molecular Endocrinology, vol. 27, no. 1, pp. 1–9, 2001.
  30. T. Masuda, K. Wada, and A. Nakajima, “Critical role of peroxisome proliferator-activated receptor γ on anoikis and invasion of squamous cell carcinoma,” Clinical Cancer Research, vol. 11, no. 11, pp. 4012–4021, 2005. View at Publisher · View at Google Scholar · View at PubMed
  31. P. L. Feldman, M. H. Lambert, and B. R. Henke, “PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?” Current Topics in Medicinal Chemistry, vol. 8, no. 9, pp. 728–749, 2008. View at Publisher · View at Google Scholar
  32. C. E. Clay, A. M. Namen, G.-I. Atsumi, et al., “Magnitude of peroxisome proliferator-activated receptor-γ activation is associated with important and seemingly opposite biological responses in breast cancer cells,” Journal of Investigative Medicine, vol. 49, no. 5, pp. 413–420, 2001.
  33. E. C. Jaeckel, S. Raja, J. Tan, et al., “Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor δ with head and neck squamous cell carcinoma,” Archives of Otolaryngology—Head & Neck Surgery, vol. 127, no. 10, pp. 1253–1259, 2001.
  34. H. P. Koeffler, “Peroxisome proliferator-activated receptor gamma and cancers,” Clinical Cancer Research, vol. 9, no. 1, pp. 1–9, 2003.
  35. A. F. Badawi and M. Z. Badr, “Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma,” International Journal of Oncology, vol. 20, no. 6, pp. 1109–1122, 2002.
  36. L. Kopelovich, J. R. Fay, R. I. Glazer, and J. A. Crowell, “Peroxisome proliferatoractivated receptor modulators as potential chemopreventive agents,” Molecular Cancer Therapeutics, vol. 1, no. 5, pp. 357–363, 2002.
  37. K. Nakashiro, N. M. Begum, D. Uchida, et al., “Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma,” Oral Oncology, vol. 39, no. 8, pp. 855–861, 2003.
  38. D. Panigrahy, S. Singer, L. Q. Shen, et al., “PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,” The Journal of Clinical Investigation, vol. 110, no. 7, pp. 923–932, 2002.
  39. D. Panigrahy, L. Q. Shen, M. W. Kieran, and A. Kaipainen, “Therapeutic potential of thiazolidinediones as anticancer agents,” Expert Opinion on Investigational Drugs, vol. 12, no. 12, pp. 1925–1937, 2003. View at Publisher · View at Google Scholar · View at PubMed
  40. I. Papadaki, E. Mylona, I. Giannopoulou, S. Markaki, A. Keramopoulos, and L. Nakopoulou, “PPARgamma expression in breast cancer: clinical value and correlation with ERbeta,” Histopathology, vol. 46, no. 1, pp. 37–42, 2005.
  41. T. Baetz, E. Eisenhauer, L. Siu, et al., “A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours,” Investigational New Drugs, vol. 25, no. 3, pp. 217–225, 2007. View at Publisher · View at Google Scholar · View at PubMed
  42. E. Kebebew, M. Peng, E. Reiff, et al., “A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer,” Surgery, vol. 140, no. 6, pp. 960–967, 2006. View at Publisher · View at Google Scholar · View at PubMed
  43. T. L. Whiteside, “The tumor microenvironment and its role in promoting tumor growth,” Oncogene, vol. 27, no. 45, pp. 5904–5912, 2008. View at Publisher · View at Google Scholar · View at PubMed
  44. N. Wang, “PPAR-δ in vascular pathophysiology,” PPAR Research, vol. 2008, Article ID 164163, 10 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
  45. E. H. Kim and Y. J. Surh, “The role of 15-deoxy-delta(12,14)-prostaglandin J(2), an endogenous ligand of peroxisome proliferator-activated receptor gamma, in tumor angiogenesis,” Biochemical Pharmacology, vol. 76, no. 11, pp. 1544–1553, 2008.
  46. T. T. Schug, D. C. Berry, N. S. Shaw, S. N. Travis, and N. Noy, “Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors,” Cell, vol. 129, no. 4, pp. 723–733, 2007. View at Publisher · View at Google Scholar · View at PubMed
  47. C. Rochette-Egly, “Nuclear receptors: integration of multiple signalling pathways through phosphorylation,” Cellular Signalling, vol. 15, no. 4, pp. 355–366, 2003. View at Publisher · View at Google Scholar
  48. L. J. Donato, J. H. Suh, and N. Noy, “Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene Btg2 is a direct target for retinoic acid receptor signaling,” Cancer Research, vol. 67, no. 2, pp. 609–615, 2007. View at Publisher · View at Google Scholar · View at PubMed
  49. L. J. Donato and N. Noy, “Suppression of mammary carcinoma growth by retinoic acid: proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein II signaling,” Cancer Research, vol. 65, no. 18, pp. 8193–8199, 2005. View at Publisher · View at Google Scholar · View at PubMed
  50. D. R. Soprano, P. Qin, and K. J. Soprano, “Retinoic acid receptors and cancers,” Annual Review of Nutrition, vol. 24, pp. 201–221, 2004. View at Publisher · View at Google Scholar · View at PubMed
  51. R. S. Uma, K. N. Naresh, A. K. D'Cruz, R. Mulherkar, and A. M. Borges, “Metastasis of squamous cell carcinoma of the oral tongue is associated with downregulation of epidermal fatty acid binding protein (E-FABP),” Oral Oncology, vol. 43, no. 1, pp. 27–32, 2007.
  52. I. Martinez, J. Wang, K. F. Hobson, R. L. Ferris, and S. A. Khan, “Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas,” European Journal of Cancer, vol. 43, no. 2, pp. 415–432, 2007. View at Publisher · View at Google Scholar · View at PubMed
  53. S. B. Baylin and J. E. Ohm, “Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction?” Nature Reviews Cancer, vol. 6, no. 2, pp. 107–116, 2006. View at Publisher · View at Google Scholar · View at PubMed
  54. A. K. Virmani, A. Rathi, S. Zöchbauer-Müller, et al., “Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas,” Journal of the National Cancer Institute, vol. 92, no. 16, pp. 1303–1307, 2000.
  55. S. M. Sirchia, A. T. Ferguson, E. Sironi, et al., “Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells,” Oncogene, vol. 19, no. 12, pp. 1556–1563, 2000.
  56. E. M. Youssef, D. Lotan, J. P. Issa, et al., “Hypermethylation of the retinoic acid receptor-β(2) gene in head and neck carcinogenesis,” Clinical Cancer Research, vol. 10, no. 5, pp. 1733–1742, 2004.
  57. K. Nason-Burchenal, D. Gandini, M. Botto, et al., “Interferon augments PML and PML/RARα expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line,” Blood, vol. 88, no. 10, pp. 3926–3936, 1996.
  58. D. R. Shalinsky, E. D. Bischoff, W. W. Lamph, et al., “A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice,” Cancer Research, vol. 57, no. 1, pp. 162–168, 1997.
  59. W. K. Hong, M. R. Spitz, and S. M. Lippman, “Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets,” Journal of Clinical Oncology, vol. 18, no. 21, supplement, pp. 9s–18s, 2000.
  60. S. M. Lippman and R. Lotan, “Advances in the development of retinoids as chemopreventive agents,” Journal of Nutrition, vol. 130, supplement, no. 2, pp. 479S–482S, 2000.
  61. P. Germain, P. Chambon, G. Eichele, et al., “International union of pharmacology. LX. Retinoic acid receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 712–725, 2006. View at Publisher · View at Google Scholar · View at PubMed
  62. N. van Zandwijk, O. Dalesio, U. Pastorino, N. de Vries, and H. van Tinteren, “EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups,” Journal of the National Cancer Institute, vol. 92, no. 12, pp. 977–986, 2000.
  63. F. McGregor, A. Muntoni, J. Fleming, et al., “Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine,” Cancer Research, vol. 62, no. 16, pp. 4757–4766, 2002.
  64. R. Ralhan, N. Chakravarti, J. Kaur, et al., “Clinical significance of altered expression of retinoid receptors in oral precancerous and cancerous lesions: relationship with cell cycle regulators,” International Journal of Cancer, vol. 118, no. 5, pp. 1077–1089, 2006. View at Publisher · View at Google Scholar · View at PubMed
  65. R. Ralhan and J. Kaur, “Retinoids as chemopreventive agents,” Journal of Biological Regulators and Homeostatic Agents, vol. 17, no. 1, pp. 66–91, 2003.
  66. R. Lotan, X.-C. Xu, S. M. Lippman, et al., “Suppression of retinoic acid receptor-β in premalignant oral lesions and its up-regulation by isotretinoin,” The New England Journal of Medicine, vol. 332, no. 21, pp. 1405–1410, 1995. View at Publisher · View at Google Scholar
  67. B. Pavan, C. Biondi, and A. Dalpiaz, “Nuclear retinoic acid receptor beta as a tool in chemoprevention trials,” Current Medicinal Chemistry, vol. 13, no. 29, pp. 3553–3563, 2006. View at Publisher · View at Google Scholar
  68. J. M. Wrangle and F. R. Khuri, “Chemoprevention of squamous cell carcinoma of the head and neck,” Current Opinion in Oncology, vol. 19, no. 3, pp. 180–187, 2007. View at Publisher · View at Google Scholar · View at PubMed
  69. G. Bug, M. Ritter, B. Wassmann, et al., “Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia,” Cancer, vol. 104, no. 12, pp. 2717–2725, 2005. View at Publisher · View at Google Scholar · View at PubMed
  70. C. D. Venkov, A. B. Rankin, and D. E. Vaughan, “Identification of authentic estrogen receptor in cultured endothelial cells: a potential mechanism for steroid hormone regulation of endothelial function,” Circulation, vol. 94, no. 4, pp. 727–733, 1996.
  71. Y. Omoto, Y. Kobayashi, K. Nishida, et al., “Expression, function, and clinical implications of the estrogen receptor β in human lung cancers,” Biochemical and Biophysical Research Communications, vol. 285, no. 2, pp. 340–347, 2001. View at Publisher · View at Google Scholar · View at PubMed
  72. S. Marsigliante, A. Muscella, L. Resta, and C. Storelli, “Human larynx expresses isoforms of the oestrogen receptor,” Cancer Letters, vol. 99, no. 2, pp. 191–196, 1996. View at Publisher · View at Google Scholar
  73. R. Kalayarasan, N. Ananthakrishnan, V. Kate, and D. Basu, “Estrogen and progesterone receptors in esophageal carcinoma,” Diseases of the Esophagus, vol. 21, no. 4, pp. 298–303, 2008. View at Publisher · View at Google Scholar · View at PubMed
  74. T. Nozoe, T. Oyama, M. Takenoyama, T. Hanagiri, K. Sugio, and K. Yasumoto, “Significance of immunohistochemical expression of estrogen receptors α and β in squamous cell carcinoma of the esophagus,” Clinical Cancer Research, vol. 13, no. 14, pp. 4046–4050, 2007. View at Publisher · View at Google Scholar · View at PubMed
  75. E. Vattemi, C. Graiff, T. Sava, R. Pedersini, A. Caldara, and M. Mandara, “Systemic therapies for recurrent and/or metastatic salivary gland cancers,” Expert Review of Anticancer Therapy, vol. 8, no. 3, pp. 393–402, 2008.
  76. T. K. S. Ku and D. L. Crowe, “Coactivator-mediated estrogen response in human squamous cell carcinoma lines,” Journal of Endocrinology, vol. 193, no. 1, pp. 147–155, 2007. View at Publisher · View at Google Scholar · View at PubMed
  77. P. Balakumar, M. Rose, S. S. Ganti, P. Krishan, and M. Singh, “PPAR dual agonists: are they opening Pandora's Box?” Pharmacological Research, vol. 56, no. 2, pp. 91–98, 2007. View at Publisher · View at Google Scholar · View at PubMed
  78. H. Ishida, K. Wada, T. Masuda, et al., “Critical role of estrogen receptor on anoikis and invasion of squamous cell carcinoma,” Cancer Science, vol. 98, no. 5, pp. 636–643, 2007. View at Publisher · View at Google Scholar · View at PubMed
  79. A. S. Rocha, R. Marques, I. Bento, et al., “Thyroid hormone receptor β mutations in the ‘hot-spot region’ are rare events in thyroid carcinomas,” Journal of Endocrinology, vol. 192, no. 1, pp. 83–86, 2007. View at Publisher · View at Google Scholar · View at PubMed
  80. P. P. Hsu and D. M. Sabatini, “Cancer cell metabolismml: warburg and beyond,” Cell, vol. 134, no. 5, pp. 703–707, 2008.
  81. J. B. Biggins and J. T. Koh, “Chemical biology of steroid and nuclear hormone receptors,” Current Opinion in Chemical Biology, vol. 11, no. 1, pp. 99–110, 2007. View at Publisher · View at Google Scholar · View at PubMed